A Phase 2 interventional study of Encapsulated Rapamycin (eRapa) in Familial Adenomatous Polyposis, sponsored by Rapamycin Holdings Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Rapamycin Holdings Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2021, is one of 8 in phase 2, and was the 25th registered.
92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.
Browse Adenomatous Polyposis Coli studies →12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
HonorHealth Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Rapamycin Holdings Inc. · Sites in United States, Denmark, Germany and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 3
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.
Median enrollment 42 across the 27 interventional studies, 833 across the 12 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 39 have an industry lead sponsor. The 10 most frequent:
Rapamycin Holdings Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Rapamycin Holdings Inc. has 2 studies filed under Adenomatous Polyposis Coli — fewer than ten, so there is no comparison to draw.
6 of the studies in Adenomatous Polyposis Coli with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04678011Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy | 2026-11 |
| NCT04677998Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis | 2026-11 |
| NCT05919264Parabilis Medicines, Inc.FOG-001 in Locally Advanced or Metastatic Solid Tumors | 2027-04-01 |
| NCT05552755Recursion Pharmaceuticals Inc.Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | 2027-06 |
| NCT06557733National Cancer Institute (NCI)An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored.
This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up.
The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.
Once the recommended phase 2 dose (RP2D) is identified, subjects will undergo evaluation under fed and fasted states to determine the food effect on eRapa absorption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will receive 0.5mg of eRapa every other day.
Drug: Encapsulated Rapamycin (eRapa)
Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
Drug: Encapsulated Rapamycin (eRapa)
Cohort 3 will receive 0.5 mg of eRapa daily.
Drug: Encapsulated Rapamycin (eRapa)
Upon identification of the RP2D, after a 2 week washout (14 days), subjects will be randomized into a fed and fasted (2 weeks - 14 days) two period cross over, with an intervening 2 week washout (14 days) for a total of 2 months (8 weeks).
Drug: Encapsulated Rapamycin (eRapa)
eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
Also known as: eRapa; Encapsulated sirolimus
Percent Change From Baseline in Colorectal Polyp Burden at Month 6
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.
Time frame: 6 months
Percent Change From Baseline in Colorectal Polyp Burden at Month 12
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: \[(Month 12 polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.
Time frame: 12 months.
Clinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.
The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Familial Adenomatous Polyposis (FAP) Staging System is a validated clinical scoring system used to assess the severity of polyposis in patients with FAP. Staging is based on polyp number, size, endoscopic resectability, and the presence of advanced pathology. The scale consists of a single overall stage (0-4) and does not include subscale scores: Stage 0 = 0-10 polyps, all \<5 mm; Stage 1 = 10-25 polyps, predominantly \<5 mm, none \>1 cm; Stage 2 = 10-25 polyps with ≥1 polyp \>1 cm, all amenable to complete removal; Stage 3 = \>25 polyps amenable to complete removal, an incompletely removed sessile polyp, or high-grade dysplasia; Stage 4 = high-grade dysplasia in an incompletely removed lesion and/or invasive colorectal cancer. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
Time frame: Following patients out to 6 and 12 months.
Clinical Effect of eRapa on Spigelman Stage Score.
The Spigelman Staging System is a validated clinical scoring system used to assess the severity of duodenal polyposis in patients with Familial Adenomatous Polyposis (FAP). The score is based on four components evaluated during upper endoscopy: number of duodenal adenomas, size of the largest adenoma, histology, and degree of dysplasia. Points are assigned to each component and summed to generate a total score ranging from 0 to 12. The overall stage is classified as Stage 0 (0 points), Stage I (1-4 points), Stage II (5-6 points), Stage III (7-8 points), or Stage IV (9-12 points), with higher stages indicating more severe duodenal disease. The measure consists of a single overall stage and does not include subscale scores. Reported values represent absolute Spigelman stage at each assessment timepoint. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
Time frame: Following patients out to 6 and 12 months.
Percent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline and at Months 6 (180 days) and 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated separately for the Month 6 and Month 12 assessments as: \[(follow-up polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.
Time frame: Following patients out to 6 and 12 months.
Determine the Effect of Food on eRapa Absorption cMax
Cmax pharmacokinetic parameters to assess the effect of food on the bioavailability of the anticipated RP2D
Time frame: 2 months
Determine the Effect of Food on eRapa Absorption AUC
AUC₀-∞ Pharmakinetic parameters to assess the effect of food on eRapa absorption
Time frame: 2 months
Sum of Diameters of Eligible Colorectal Polyps at Baseline
Colorectal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible colorectal polyp was measured. Baseline colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
Time frame: baseline
Sum of Diameters of Eligible Duodenal Polyps at Baseline
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Baseline duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
Time frame: baseline
Participants were recruited and screened for eligibility at the study site(s). Eligible participants were enrolled into the dose-escalation phase (Part 1) and assigned sequentially to Cohorts 1-3. Participants who completed Part 1 and continued to meet eligibility criteria were eligible to enroll in the food-effect crossover phase (Part 2), in which participants were randomized to one of two treatment sequences (Fed → Fasted or Fasted → Fed).
| Milestone | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Part 2 Food Effect Crossover: Fed→Fasted Sequence | Part 2: Food Effect Crossover - Fasted→Fed Sequence |
|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 0 | 0 |
| Completed | 10 | 8 | 8 | 0 | 0 |
| Not completed | 0 | 2 | 2 | 0 | 0 |
| Milestone | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Part 2 Food Effect Crossover: Fed→Fasted Sequence | Part 2: Food Effect Crossover - Fasted→Fed Sequence |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 | 10 |
| Completed | 0 | 0 | 0 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 3 | 2 |
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.
| percent change polyp burden | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| Percent Change From Baseline in Colorectal Polyp Burden at Month 6 | 26.40 ± 170.474 | -10.84 ± 62.041 | 269.79 ± 668.411 |
Colorectal polyp burden was assessed by colonoscopy at baseline and Month 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: \[(Month 12 polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.
| Percent Change Polyp Burden | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| Percent Change From Baseline in Colorectal Polyp Burden at Month 12 | 72.55 ± 157.675 | -1.24 ± 81.323 | 679.64 ± 1551.148 |
The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Familial Adenomatous Polyposis (FAP) Staging System is a validated clinical scoring system used to assess the severity of polyposis in patients with FAP. Staging is based on polyp number, size, endoscopic resectability, and the presence of advanced pathology. The scale consists of a single overall stage (0-4) and does not include subscale scores: Stage 0 = 0-10 polyps, all \<5 mm; Stage 1 = 10-25 polyps, predominantly \<5 mm, none \>1 cm; Stage 2 = 10-25 polyps with ≥1 polyp \>1 cm, all amenable to complete removal; Stage 3 = \>25 polyps amenable to complete removal, an incompletely removed sessile polyp, or high-grade dysplasia; Stage 4 = high-grade dysplasia in an incompletely removed lesion and/or invasive colorectal cancer. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
| units on a scale | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| 6 month analysis | 1.9 ± 1.1 | 1.9 ± 1.29 | 1.7 ± 1.41 |
| 12 month analysis | 2.0 ± 1.05 | 1.8 ± 1.3 | 1.7 ± 1.42 |
| Baseline | 2.5 ± 0.85 | 2.3 ± 0.95 | 1.8 ± 1.03 |
The Spigelman Staging System is a validated clinical scoring system used to assess the severity of duodenal polyposis in patients with Familial Adenomatous Polyposis (FAP). The score is based on four components evaluated during upper endoscopy: number of duodenal adenomas, size of the largest adenoma, histology, and degree of dysplasia. Points are assigned to each component and summed to generate a total score ranging from 0 to 12. The overall stage is classified as Stage 0 (0 points), Stage I (1-4 points), Stage II (5-6 points), Stage III (7-8 points), or Stage IV (9-12 points), with higher stages indicating more severe duodenal disease. The measure consists of a single overall stage and does not include subscale scores. Reported values represent absolute Spigelman stage at each assessment timepoint. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.
| score on a scale | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| 6 Month analysis | 2.1 ± 1.05 | 2.0 ± 1.07 | 1.8 ± 0.84 |
| 12 month analysis | 2.0 ± 0.87 | 2.1 ± 0.9 | 1.6 ± 0.98 |
| Baseline | 2.2 ± 0.83 | 2.1 ± 1.17 | 1.3 ± 1.12 |
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline and at Months 6 (180 days) and 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated separately for the Month 6 and Month 12 assessments as: \[(follow-up polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.
| Percent Change Polyp Burden | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| 6 month analysis | -34.82 ± 41.712 | 32.64 ± 115.920 | 103.38 ± 122.222 |
| 12 month analysis | 20.90 ± 80.677 | 35.77 ± 70.926 | 131.52 ± 200.868 |
Cmax pharmacokinetic parameters to assess the effect of food on the bioavailability of the anticipated RP2D
| ng/ml | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions | Food-Effect Crossover, Part 2: Rapa RP2D Pharmacokinetics Under Fasted Conditions |
|---|---|---|
| Determine the Effect of Food on eRapa Absorption cMax | 1.96 ± 60.667 | 3.58 ± 62.606 |
AUC₀-∞ Pharmakinetic parameters to assess the effect of food on eRapa absorption
| ng*min/mL | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions | Food-Effect Crossover, Part 2: Rapa RP2D Pharmacokinetics Under Fasted Conditions |
|---|---|---|
| Determine the Effect of Food on eRapa Absorption AUC | 1479.59 ± 31.827 | 2564.92 ± 47.812 |
Colorectal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible colorectal polyp was measured. Baseline colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
| mm | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| Sum of Diameters of Eligible Colorectal Polyps at Baseline | 325.9 ± 370.54 | 224.8 ± 244.91 | 75.1 ± 91.81 |
Duodenal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Baseline duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.
| mm | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 |
|---|---|---|---|
| Sum of Diameters of Eligible Duodenal Polyps at Baseline | 75.30 ± 127.50 | 53.80 ± 71.50 | 24.3 ± 28.96 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1, Cohort 1 | 0/10 (0%) | 5/10 (50%) | 9/10 (90%) |
| Part 1, Cohort 2 | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| Part 1, Cohort 3 | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions | 0/8 (0%) | 1/8 (12.5%) | 4/8 (50%) |
| Event | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions |
|---|---|---|---|---|---|
| Small intestinal obstuctionGastrointestinal disorders | 2/10 | 0/10 | 1/10 | 1/7 | 1/8 |
| PancreatitisGastrointestinal disorders | 1/10 | 0/10 | 1/10 | 0/7 | 0/8 |
| Rectal haemorrhageGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/7 | 0/8 |
| BradycardiaCardiac disorders | 0/10 | 0/10 | 1/10 | 0/7 | 0/8 |
| Bile duct stoneHepatobiliary disorders | 0/10 | 1/10 | 0/10 | 0/7 | 0/8 |
| Gastroenteritis rotavirusInfections and infestations | 1/10 | 0/10 | 0/10 | 0/7 | 0/8 |
| Event | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions | Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/10 | 2/10 | 3/10 | 1/7 | 1/8 |
| StomatitisGastrointestinal disorders | 1/10 | 0/10 | 3/10 | 0/7 | 0/8 |
| NauseaGastrointestinal disorders | 2/10 | 1/10 | 1/10 | 0/7 | 0/8 |
| Rectal haemorrhageGastrointestinal disorders | 2/10 | 1/10 | 0/10 | 0/7 | 0/8 |
| Small intestinal obstructionGastrointestinal disorders | 2/10 | 0/10 | 1/10 | 1/7 | 1/8 |
| VomitingGastrointestinal disorders | 0/10 | 0/10 | 2/10 | 0/7 | 0/8 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/10 | 0/10 | 0/10 | 0/7 | 0/8 |
| HypokalaemiaMetabolism and nutrition disorders | 1/10 | 0/10 | 2/10 | 0/7 | 0/8 |
| ConstipationGastrointestinal disorders | 1/10 | 0/10 | 1/10 | 1/7 | 0/8 |
| Dry mouthGastrointestinal disorders | 1/10 | 0/10 | 1/10 | 1/7 | 0/8 |
The food effect participants were selected from Cohorts 1, 2 or 3 - it was a sub-study so participants are not counted twice
| Age, Categorical(Participants) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 10 | 30 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 45 ± 12.09 | 43.9 ± 8.71 | 48.1 ± 12.94 | 46.75 ± 11.01 |
| Sex: Female, Male(Participants) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| Female | 2 | 6 | 7 | 15 |
| Male | 8 | 4 | 3 | 15 |
| Race (NIH/OMB)(Participants) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 10 | 10 | 10 | 30 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 9 | 9 | 9 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 10 | 30 |
| Polyp Burden(Number of polyps) | Part 1, Cohort 1 | Part 1, Cohort 2 | Part 1, Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 325.9 ± 370.54 | 224.8 ± 244.91 | 75.1 ± 95.81 | 208.6 ± 273.54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2021 to primary completion in Dec 2024, 46 months.
Results were first posted in Oct 2026, 1 year 10 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2025 → Dec 2024 and completion Mar 2025 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Encapsulated Rapamycin
Rapamycin Holdings Inc.